MDT

87.13

-1.01%↓

A

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

A

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

A

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

A

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

A

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Search

Charles River Laboratories International Inc

Abrir

SetorSaúde

180.73 0.81

Visão Geral

Variação de preço das ações

24h

Atual

Mín

177.85

Máximo

183.89

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+10.03% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

859M

8.8B

Abertura anterior

179.92

Fecho anterior

180.73

Sentimento de Notícias

By Acuity

24%

76%

53 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de abr. de 2026, 23:36 UTC

Aquisições, Fusões, Aquisições de Empresas

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 de abr. de 2026, 23:24 UTC

Ações em Alta

Stocks to Watch: Gloo, Broadcom, GitLab

14 de abr. de 2026, 22:42 UTC

Aquisições, Fusões, Aquisições de Empresas

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 de abr. de 2026, 21:32 UTC

Grandes Movimentos do Mercado

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 de abr. de 2026, 23:54 UTC

Conversa de Mercado

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 de abr. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 de abr. de 2026, 22:54 UTC

Ganhos

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 de abr. de 2026, 22:54 UTC

Ganhos

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 de abr. de 2026, 22:54 UTC

Ganhos

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 de abr. de 2026, 22:54 UTC

Ganhos

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 de abr. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 de abr. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 de abr. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 de abr. de 2026, 22:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 de abr. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 de abr. de 2026, 22:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 de abr. de 2026, 22:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 de abr. de 2026, 22:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 de abr. de 2026, 22:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 de abr. de 2026, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

14 de abr. de 2026, 20:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 de abr. de 2026, 20:32 UTC

Ações em Alta

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 de abr. de 2026, 19:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 de abr. de 2026, 19:38 UTC

Ganhos

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 de abr. de 2026, 19:27 UTC

Conversa de Mercado

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 de abr. de 2026, 19:21 UTC

Conversa de Mercado
Notícias Principais

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 de abr. de 2026, 19:09 UTC

Aquisições, Fusões, Aquisições de Empresas

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 de abr. de 2026, 18:30 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 de abr. de 2026, 18:30 UTC

Conversa de Mercado

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

10.03% parte superior

Previsão para 12 meses

Média 197.3 USD  10.03%

Máximo 235 USD

Mínimo 160 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

7

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

53 / 348 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat